Media coverage about BioDelivery Sciences International (NASDAQ:BDSI) has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioDelivery Sciences International earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 45.9107300604177 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference – GlobeNewswire (press release) (globenewswire.com)
- Francis E. Odonnell, Jr. Sells 113,876 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock (americanbankingnews.com)
- BioDelivery Sciences International, Inc. (BDSI) stock locked down along -15.20% to its 50- SMA – The Stocks News (press release) (thestocksnews.com)
- BioDelivery Sciences International (BDSI) Scheduled to Post Quarterly Earnings on Thursday (americanbankingnews.com)
BioDelivery Sciences International (NASDAQ:BDSI) traded up $0.05 on Wednesday, hitting $2.20. The stock had a trading volume of 157,879 shares, compared to its average volume of 475,164. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.28 and a quick ratio of 1.07. BioDelivery Sciences International has a twelve month low of $1.55 and a twelve month high of $3.60. The firm has a market capitalization of $120.15, a PE ratio of -11.58 and a beta of 0.51.
In related news, Director Mark A. Sirgo sold 162,509 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $2.78, for a total value of $451,775.02. Following the transaction, the director now owns 1,759,262 shares in the company, valued at approximately $4,890,748.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark A. Sirgo sold 108,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $2.57, for a total value of $277,560.00. Following the completion of the transaction, the director now owns 1,759,262 shares in the company, valued at approximately $4,521,303.34. The disclosure for this sale can be found here. Insiders sold a total of 1,093,887 shares of company stock worth $2,909,970 in the last 90 days. 7.73% of the stock is currently owned by insiders.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.